APICES acknowledged for its role in the GGCP 081/21 Study
How does first-line osimertinib perform for advanced EGFR-mutated NSCLC in routine care in Spain? The GGCP 081/21 retrospective study addresses effectiveness and safety in a real-world setting, and APICES was acknowledged for supporting analysis and publication activities.
We are proud to announce that APICES has been acknowledged for its ongoing collaboration in the GGCP 081/21 study, an Observational retrospective study in Lung Cancer (NSCLC). This acknowledgement was highlighted in the Journal of Clinical and Translational Oncology.
This acknowledgment is a great motivation for the entire APICES team to continue the commitment we bring to every project we collaborate on. We sincerely thank Astrazeneca Spain and Dra. Maria Carmen Areses Manrique for giving us the opportunity to support the study as CRO and for including us acknowledgments. We also congratulate them and all investigators and patients on the GGCP 081/21 Study progress and results.
The GGCP 081/21 study aims to evaluate the effectiveness and safety of osimertinib as a first-line therapy in patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC) in a Spanish real-world setting.
On integration, change leadership, and strengthening Apices as one unified organization In a clinical research environment where sponsors value stability, predictability, and quality above all else, organizational change must be approached with care. As APICES...
RWE and HEOR have moved from supporting inputs to decision-critical evidence across development and access. This article summarises what teams are using them for today, how evidence generation is changing, and where AI adds value when paired with the right governance.
Stage III NSCLC care sits at the intersection of multimodal treatment and real-world constraints. The GEOCP-SEOR population-based study describes how patients are managed across Spain, and APICES was acknowledged for supporting the publication through medical editorial assistance.